Search Results - "Lee, Jae Lyun"

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial by Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., Choueiri, Toni K.

“…We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial ( n  = 886; NCT02684006 ), which demonstrated significantly…”
Get full text

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma by Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

“…In a phase 3 clinical trial involving previously treated patients with advanced renal-cell carcinoma, progression-free survival was significantly longer with…”
Get full text

Clinical features and oncological outcomes of primary female urethral cancer by Lee, Wonchul, Yu, Jesang, Lee, Jae‐Lyun, Kim, Young Seok, Hong, Bumsik

“…Purpose Investigation of the clinical features and treatment outcomes of primary female urethral cancer (FUC) at a single institution. Materials and Methods We…”
Get full text

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study by Ko, Jenny J, MD, Xie, Wanling, MS, Kroeger, Nils, MD, Lee, Jae-lyun, MD, Rini, Brian I, MD, Knox, Jennifer J, MD, Bjarnason, Georg A, MD, Srinivas, Sandy, MD, Pal, Sumanta K, MD, Yuasa, Takeshi, MD, Smoragiewicz, Martin, MD, Donskov, Frede, MD, Kanesvaran, Ravindran, MD, Wood, Lori, MD, Ernst, D Scott, MD, Agarwal, Neeraj, MD, Vaishampayan, Ulka N, MD, Rha, Sun-young, MD, Choueiri, Toni K, MD, Heng, Daniel Y C, Dr

“…Summary Background Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the…”
Get full text

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations by Albiges, Laurence, Hakimi, A Ari, Xie, Wanling, McKay, Rana R, Simantov, Ronit, Lin, Xun, Lee, Jae-Lyun, Rini, Brian I, Srinivas, Sandy, Bjarnason, Georg A, Ernst, Scott, Wood, Lori A, Vaishamayan, Ulka N, Rha, Sun-Young, Agarwal, Neeraj, Yuasa, Takeshi, Pal, Sumanta K, Bamias, Aristotelis, Zabor, Emily C, Skanderup, Anders J, Furberg, Helena, Fay, Andre P, de Velasco, Guillermo, Preston, Mark A, Wilson, Kathryn M, Cho, Eunyoung, McDermott, David F, Signoretti, Sabina, Heng, Daniel Y C, Choueiri, Toni K

“…Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be…”
Get full text

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial by Motzer, Robert J, Dr Prof, Porta, Camillo, MD, Vogelzang, Nicholas J, Prof, Sternberg, Cora N, MD, Szczylik, Cezary, Prof, Zolnierek, Jakub, MD, Kollmannsberger, Christian, MD, Rha, Sun Young, MD, Bjarnason, Georg A, MD, Melichar, Bohuslav, Prof, De Giorgi, Ugo, MD, Grünwald, Viktor, Prof, Davis, Ian D, MBBS, Lee, Jae-Lyun, Prof, Esteban, Emilio, Prof, Urbanowitz, Gladys, MBA, Cai, Can, PhD, Squires, Matthew, PhD, Marker, Mahtab, PhD, Shi, Michael M, MD, Escudier, Bernard, Prof

“…Summary Background An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor…”
Get full text

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration by Ravi, Praful, Pond, Gregory R., Diamantopoulos, Leonidas N., Su, Christopher, Alva, Ajjai, Jain, Rohit K., Skelton, William P., Gupta, Sumati, Tward, Jonathan D., Olson, Kathleen M., Singh, Parminder, Grunewald, Camilla M., Niegisch, Guenter, Lee, Jae‐Lyun, Gallina, Andrea, Bandini, Marco, Necchi, Andrea, Mossanen, Matthew, McGregor, Bradley A., Curran, Catherine, Grivas, Petros, Sonpavde, Guru P.

“…Objectives To evaluate outcomes of patients achieving a post‐treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant…”
Get full text

Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma by Hwang, Hee Sang, Go, Heounjeong, Park, Ja-Min, Yoon, Sun Young, Lee, Jae-Lyun, Jeong, Se Un, Cho, Yong Mee

“…Tyrosine kinase inhibitors (TKIs) are widely accepted as treatment for metastatic clear cell renal cell carcinoma (ccRCC). However, most patients eventually…”
Get full text

The Association Between PD‐L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor‐Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma by Shin, Su‐Jin, Jeon, Yoon Kyung, Cho, Yong Mee, Lee, Jae‐Lyun, Chung, Doo Hyun, Park, Ji Young, Go, Heounjeong

“…Background. Vascular endothelial growth factor pathway (VEGF)‐tyrosine kinase inhibitors (TKIs) are used as the first‐line treatment for patients with…”
Get full text

FGFR1 is associated with c‐MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti‐angiogenic therapy by Park, Jee Young, Kim, Pil‐Jong, Shin, Su‐Jin, Lee, Jae‐Lyun, Cho, Yong Mee, Go, Heounjeong

“…Aims This study aimed to investigate the clinicopathological significance of FGFR1 and c‐MYC expression, particularly in relation to angiogenesis in clear cell…”
Get full text

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region by Eto, Masatoshi, Lee, Jae‐Lyun, Chang, Yen‐Hwa, Gao, Seasea, Singh, Manmohan, Gurney, Howard

“…Until recently, international and Asia‐specific guidelines for advanced urothelial carcinoma (UC) recommended first‐line (1L) platinum‐based chemotherapy,…”
Get full text

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma by Sonpavde, Guru, Pond, Gregory R, Choueiri, Toni K, Mullane, Stephanie, Niegisch, Guenter, Albers, Peter, Necchi, Andrea, Di Lorenzo, Giuseppe, Buonerba, Carlo, Rozzi, Antonio, Matsumoto, Kazumasa, Lee, Jae-Lyun, Kitamura, Hiroshi, Kume, Haruki, Bellmunt, Joaquim

“…Abstract Background Single-agent taxanes are commonly used as salvage systemic therapy for patients with advanced urothelial carcinoma (UC). Objective To study…”
Get full text

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by Ruiz-Morales, Jose Manuel, Swierkowski, Marcin, Wells, J. Connor, Fraccon, Anna Paola, Pasini, Felice, Donskov, Frede, Bjarnason, Georg A, Lee, Jae-Lyun, Sim, Hao-Wen, Sliwczynsk, Andrzej, Ptak-Chmielewska, Aneta, Teter, Zbigniew, Beuselinck, Benoit, Wood, Lori A, Yuasa, Takeshi, Pezaro, Carmel, Rini, Brian I, Szczylik, Cezary, Choueiri, Toni K, Heng, Daniel Y.C

“…Abstract Background Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). However, how…”
Get full text

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy by Wit, Ronald, Powles, Thomas, Castellano, Daniel, Necchi, Andrea, Lee, Jae‐Lyun, Heijden, Michiel S., Matsubara, Nobuaki, Bamias, Aristotelis, Fléchon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Zimmermann, Annamaria H., Long, Amanda, Walgren, Richard A., Gao, Ling, Bell‐McGuinn, Katherine M., Petrylak, Daniel P.

“…Aims Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need to…”
Get full text

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial by van der Heijden, Michiel S., Powles, Thomas, Petrylak, Daniel, de Wit, Ronald, Necchi, Andrea, Sternberg, Cora N., Matsubara, Nobuaki, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A., Bamias, Aristotelis, Gakis, Georgios, Lee, Jae-Lyun, Tagawa, Scott T., Vaishampayan, Ulka, Aragon-Ching, Jeanny B., Eigl, Bernie J., Hozak, Rebecca R., Rasmussen, Erik R., Xia, Meng Summer, Rhodes, Ryan, Wijayawardana, Sameera, Bell-McGuinn, Katherine M., Aggarwal, Amit, Drakaki, Alexandra

“…The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma…”
Get full text

Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis by Kim, Yeon Joo, Byun, Sang Jun, Ahn, Hanjong, Kim, Choung-Soo, Hong, Beom-Sik, Yoo, Sangjun, Lee, Jae-Lyun, Kim, Young Seok

“…Although radical cystectomy (RC) is considered as the standard therapy for muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) combining…”
Get full text

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma by Hwang, Hee Sang, Park, Yun Yong, Shin, Su Jin, Go, Heounjeong, Park, Ja Min, Yoon, Sun Young, Lee, Jae Lyun, Cho, Yong Mee

“…Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully…”
Get full text

Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients? by Yoo, Dong-Jun, Kim, Kang Mo, Jin, Young-Joo, Shim, Ju Hyun, Ko, Gi-Young, Yoon, Hyun-Ki, Sung, Kyu-Bo, Lee, Jae-Lyun, Kang, Yoon-Koo, Lim, Young-Suk, Lee, Han Chu, Chung, Young-Hwa, Lee, Yung Sang, Suh, Dong Jin

“…Background and Aims:  The therapeutic efficacy of transarterial chemoembolization (TACE) has not been evaluated in hepatocellular carcinoma (HCC) patients with…”
Get full text

Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib by YOO, Changhoon, RYU, Min-Hee, BYUNG WOOG KANG, YOON, Shin-Kyo, RYOO, Baek-Yeol, CHANG, Heung-Moon, LEE, Jae-Lyun, MO YOUL BECK, TAE WON KIM, KANG, Yoon-Koo

“…Imatinib plasma trough levels (C(min)) have been reported to correlate with treatment outcomes in patients with gastrointestinal stromal tumors (GISTs). We…”
Get full text

Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma by Lee, Jae-Lyun, MD, PhD, Kim, Song Cheol, MD, PhD, Kim, Ji-Hoon, MD, PhD, Lee, Sang Soo, MD, PhD, Kim, Tae-Won, MD, PhD, Park, Do Hyun, MD, PhD, Seo, Dong Wan, MD, PhD, Lee, Sung Koo, MD, PhD, Kim, Myung-Hwan, MD, PhD, Kim, Jong Hoon, MD, PhD, Park, Jin-Hong, MD, PhD, Shin, Sang Hyun, MD, MSc, Han, Duck Jong, MD, PhD

“…Background To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic…”
Get full text